Drug intelligence / Profile preview

JT002 (Shanghai Junshi Biosciences Co., Ltd.)

Development stage: Unknown
Lead developer: Junshi Biosciences
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intranasal

Overview

JT002 is a small nucleic acid immunomodulator being developed for the treatment of seasonal allergic rhinitis. Administered as an intranasal spray, the drug is a product of a collaboration between Junshi Biosciences (through its subsidiary Shanghai JunTop Biosciences) and JSIAMA Biopharmaceutical. It represents a novel therapeutic approach that utilizes nucleic acid technology to modulate the immune system's reaction to seasonal allergens such as pollen. JT002 is currently in Phase II clinical development, where its efficacy and safety are being evaluated across various dosing regimens in adult patients.

Beyond the preview

Go deeper on JT002 (Shanghai Junshi Biosciences Co., Ltd.).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JT002 (Shanghai Junshi Biosciences Co., Ltd.).

Explore the full profile